Adoptive immunotherapy for cancer: building on success. Substantial progress has been made in our understanding of the molecular and cellular bases of T cell mediated anti-tumor responses. T cells are potent effectors of the adaptive anti-tumor immune response. Some target antigens recognized by tumor-reactive CD8+ T cells are mutated antigens. The molecular signals that modulate T cell activation, function and memory are being elucidated. Both positive and negative signals from co-stimulatory molecules have been shown to shape the anti-tumor response. Cytokines, including those with receptors that contain the common cytokine-receptor gamma chain have been shown to alter the programming of effector CD8+ T cells. We are also characterizing the metabolic characteristics of T cells that are capable of destroying tumor. In addition, we have studied the mechanisms that tumor cells use to escape recognition by T cells. This year we our study led by scientists in the Center for Cancer Research (CCR) at the National Cancer Institute shed light on one way tumors may continue to grow despite the presence of cancer-killing immune cells. The findings, published March 29, 2019, in Science, suggest a way to enhance the effectiveness of immunotherapies for cancer treatment.
Lin, Cheng-Chao; Kurashige, Mahiro; Liu, Yi et al. (2018) A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Sci Rep 8:2743 |
Henning, Amanda N; Klebanoff, Christopher A; Restifo, Nicholas P (2018) Silencing stemness in T cell differentiation. Science 359:163-164 |
Henning, Amanda N; Roychoudhuri, Rahul; Restifo, Nicholas P (2018) Epigenetic control of CD8+ T cell differentiation. Nat Rev Immunol 18:340-356 |
Vizcardo, Raul; Klemen, Nicholas D; Islam, S M Rafiqul et al. (2018) Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. Cell Rep 22:3175-3190 |
Gurusamy, Devikala; Clever, David; Eil, Robert et al. (2017) Novel ""Elements"" of Immune Suppression within the Tumor Microenvironment. Cancer Immunol Res 5:426-433 |
Wang, Qiong J; Yu, Zhiya; Hanada, Ken-Ichi et al. (2017) Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clin Cancer Res 23:2267-2276 |
Slaney, Clare Y; von Scheidt, Bianca; Davenport, Alexander J et al. (2017) Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clin Cancer Res 23:2478-2490 |
Afzali, Behdad; Grönholm, Juha; Vandrovcova, Jana et al. (2017) BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. Nat Immunol 18:813-823 |
Kishton, Rigel J; Sukumar, Madhusudhanan; Restifo, Nicholas P (2017) Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab 26:94-109 |
Sukumar, Madhusudhanan; Kishton, Rigel J; Restifo, Nicholas P (2017) Metabolic reprograming of anti-tumor immunity. Curr Opin Immunol 46:14-22 |
Showing the most recent 10 out of 128 publications